Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2025)

Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Mimedx Group (NASDAQ:MDXG) is the #1 top biotech stock out of 621 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Mimedx Group (NASDAQ:MDXG) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: B.

Mimedx Group (NASDAQ:MDXG) has a Due Diligence Score of 42, which is 19 points higher than the biotech industry average of 23.

MDXG passed 13 out of 33 due diligence checks and has strong fundamentals. Mimedx Group has seen its stock lose -25.41% over the past year, overperforming other biotech stocks by 23 percentage points.

Mimedx Group has an average 1 year price target of $12.00, an upside of 76.99% from Mimedx Group's current stock price of $6.78.

Mimedx Group stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Mimedx Group, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Beone Medicines (NASDAQ:ONC) is the #2 top biotech stock out of 621 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Beone Medicines (NASDAQ:ONC) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: C, and AI: B.

Beone Medicines (NASDAQ:ONC) has a Due Diligence Score of 53, which is 30 points higher than the biotech industry average of 23.

ONC passed 18 out of 33 due diligence checks and has strong fundamentals. Beone Medicines has seen its stock return 74.83% over the past year, overperforming other biotech stocks by 123 percentage points.

Beone Medicines has an average 1 year price target of $390.88, an upside of 17.48% from Beone Medicines's current stock price of $332.71.

Beone Medicines stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Beone Medicines, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top biotech stock out of 621 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: C, Momentum: B, Sentiment: A, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 43, which is 20 points higher than the biotech industry average of 23.

AUPH passed 14 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 84.96% over the past year, overperforming other biotech stocks by 134 percentage points.

Aurinia Pharmaceuticals has an average 1 year price target of $17.67, an upside of 9.66% from Aurinia Pharmaceuticals's current stock price of $16.11.

Aurinia Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Aurinia Pharmaceuticals, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 12%, which is 9 percentage points higher than the biotech industry average of 2.94%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 2.21%, which is -1 percentage points lower than the biotech industry average of 2.94%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 49.4% indicates that its dividend yield is sustainable for the long-term.

Bio Techne (NASDAQ:TECH) has an annual dividend yield of 0.5%, which is -2 percentage points lower than the biotech industry average of 2.94%. Bio Techne's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Bio Techne's dividend has not shown consistent growth over the last 10 years.

Bio Techne's dividend payout ratio of 64% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were up 2.07% in the last day, and up 2.25% over the last week. Pasithea Therapeutics was the among the top gainers in the biotechnology industry, gaining 45.55% yesterday.

Shares of Pasithea Therapeutics are trading higher. The company announced PK and PD data from Cohort 7 in its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, or in patients who have failed prior BRAF/MEK inhibition.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 1.61% in the past year. It has overperformed other stocks in the biotech industry by 50 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 64.9% in the past year. It has overperformed other stocks in the biotech industry by 113 percentage points.

Exelixis (NASDAQ:EXEL) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Exelixis has a valuation score of 57, which is 42 points higher than the biotech industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Exelixis's stock has gained 16.14% in the past year. It has overperformed other stocks in the biotech industry by 65 percentage points.

58.95% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 45.66% over the next year.

3.53% of biotech stocks have a Zen Rating of A (Strong Buy), 6.03% of biotech stocks are rated B (Buy), 46.99% are rated C (Hold), 31.19% are rated D (Sell), and 12.27% are rated F (Strong Sell).